



Psoriasis-Two Centuries after Its Discovery: Pathogenesis and Treatment

Guest Editors:

Dr. Anna Campanati

Dr. Giulia Radi

Dr. Emanuela Martina

Dr. Federico Diotallevi

Deadline for manuscript
submissions:
closed (29 February 2024)

Message from the Guest Editors

Psoriasis is an inflammatory and immune-mediated skin disease first discovered by the medical community in the early 19th century. Researchers have learned much about psoriasis since, although the condition has a long history of misunderstandings. Nowadays, the increased knowledge about the pathogenesis and comorbidities of psoriasis has contributed to a new understanding of psoriasis as a systemic disease. At the same time, the identification of specific molecular targets has led to the emergence of a variety of modern treatments able to significantly reduce the severity of the disease and sometimes change its natural history.

The therapeutic management of psoriatic patients has changed profoundly over the last century, evolving from an exclusively topical approach to one more oriented towards the containment of systemic inflammation.

This Special Issue provides a concise overview of the long history of clinicians' understanding of psoriasis and its treatments.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPlus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
X@Biomed_MDPI